Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors—Data From the ARON-1 Study
First-line IO-based combinations provide clinically meaningful survival in sRCC, with outcomes affected by sex, metastatic sites, and IMDC risk. This RWE may support a tailored therapeutic approach on the basis of baseline prognostic factors.
Authors
- Maria Teresa Bourlon (ORCID: https://orcid.org/0000-0002-3116-912X)
- Tarek Taha (ORCID: https://orcid.org/0000-0001-7936-5245)
- Ondřej Fiala (ORCID: https://orcid.org/0000-0002-4096-7385)
- Bohuslav Melichar (ORCID: https://orcid.org/0000-0002-5474-6866)
- Umut Akova (ORCID: https://orcid.org/0000-0002-1768-0503)
- Sebastiano Buti (ORCID: https://orcid.org/0000-0003-0876-0226)
- Matteo Santoni (ORCID: https://orcid.org/0000-0001-7340-6173)
- Thomas Büttner (ORCID: https://orcid.org/0000-0003-0316-9621)
- Hatice Bölek (ORCID: https://orcid.org/0000-0001-8659-7327)
- Andrey Soares (ORCID: https://orcid.org/0000-0003-4980-6729)
- Ahmet Yildirim (ORCID: https://orcid.org/0009-0006-2542-3714)
- Marwan G. Ghosn (ORCID: https://orcid.org/0000-0003-1627-384X)
- Veronica Mollica (ORCID: https://orcid.org/0000-0002-5169-3631)
- Enrique Grande (ORCID: https://orcid.org/0000-0002-0134-4732)
- Vincenza Conteduca (ORCID: https://orcid.org/0000-0002-6921-714X)
- Javier Molina‐Cerrillo (ORCID: https://orcid.org/0000-0003-4616-0598)
- Mehmet Asım Bilen (ORCID: https://orcid.org/0000-0003-4003-1103)
- Se Hoon Park (ORCID: https://orcid.org/0000-0001-5084-9326)
- Alessandra Filosa (ORCID: https://orcid.org/0000-0002-4071-4898)
- Ray Manneh Kopp (ORCID: https://orcid.org/0000-0002-8106-9741)
- Annalisa Zeppellini (ORCID: https://orcid.org/0009-0002-2137-3140)
- Francesco Massari (ORCID: https://orcid.org/0000-0001-6476-6871)
- Alfonso Gómez de Liaño (ORCID: https://orcid.org/0000-0002-1844-8474)
- Yüksel Ürün (ORCID: https://orcid.org/0000-0002-9152-9887)
- Fernando Sabino Marques Monteiro (ORCID: https://orcid.org/0000-0002-6621-8251)
- Sarah Scagliarini (ORCID: https://orcid.org/0000-0001-5814-2296)
- Anca Florina Zgura (ORCID: https://orcid.org/0000-0002-2370-5762)
- Matteo Rosellini (ORCID: https://orcid.org/0000-0002-4920-9951)
- Jawaher Ansari (ORCID: https://orcid.org/0000-0001-5525-548X)
- Daniele Santini (ORCID: https://orcid.org/0000-0002-9118-3337)
- Alessandro Rizzo (ORCID: https://orcid.org/0000-0002-6085-648X)
- María José Juan-Fita (ORCID: https://orcid.org/0000-0002-7767-0200)
- Haoran Li (ORCID: https://orcid.org/0000-0002-8485-9378)
Institutions
- University of Foggia (IT)
- Marche Polytechnic University (IT)
- University of Parma (IT)
- Royal Marsden NHS Foundation Trust (GB)
- Ankara University (TR)
- Emory University (US)
- Saint Joseph University (LB)
- Charles University (CZ)
- University Hospital Bonn (DE)
- Hospital Israelita Albert Einstein (BR)
- Policlinico Umberto I (IT)
- Samsung Medical Center (KR)
- Popular University of Cesar (CO)
- Ospedale Antonio Cardarelli (IT)
- Tawam Hospital (AE)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- The University of Kansas Cancer Center (US)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- Fundación Instituto Valenciano de Oncología (ES)
- Azienda USL di Bologna (IT)
- Institutul Oncologic Bucuresti (RO)
- Hospital Materno-Infantil (ES)
- Istituto Tumori Bari (IT)
- Hospital Sírio-Libanês (BR)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- MD Anderson Cancer Center Madrid (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Ospedale di Macerata
- Palacký University Olomouc (CZ)
- University of Bologna (IT)
Publication Details
- Journal
- JCO Global Oncology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1200/go-25-00376
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00